Introduction:

The role of radioembolization (RE) in patients with liver metastatic colorectal cancer (mCRC) is still unclear. This research aims to assess the prognostic factors and outcomes of RE in these patients.

Methodology:

A retrospective analysis of all patients with liver mCRC who underwent RE in a single-centre institution from January 2011 to March 2020, was performed. The one-year survival was evaluated with the Kaplan-Meier method and potential prognostic factors were analysed using the log-rank test, Mann-Whitney test, chi-square test, Fisher’s test, and t-test for independent samples.

Results:

Thirty patients were analysed. The median age was 61.5 years and most patients were male (63.3%). There was a low complication rate. Successful RE (defined by tomographic response, according to RECIST 1.1 criteria, as partial, complete or stable, at three months of follow-up) was observed in 50% of the cases. Cancer stage ≤ 3 (p<0,040), CEA levels at diagnosis lower than 20ng/mL(p=0,035) and after RE (p=0,023), more than one year between diagnosis of CRC and the emergence of liver metastases (p=0,036), absence of vascular (p=0,028) or lymphatic (p=0,020) invasion at the time of diagnosis were significantly associated with a successful. The one-year survival of patients with and without successful RE was 9.4 and 8.9 months, respectively.

Conclusion:

RE is a well-tolerated therapy, with objective results in half of treated patients and a non-significant increase in patient survival. There are RE response prognostic factors that have been identified that may help to better select patients to treat.

        · resumo em Português     · texto em Português     · Português ( pdf )